Manish A. Shah

Manish A. Shah, MD is the Bartlett Family Associate Professor of Gastrointestinal Oncology and Director of the Gastrointestinal Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital. He is one of the foremost clinical investigators in gastric and gastroesophageal junction adenocarcinoma in North America, with particular expertise in HER2-targeted therapy, immunotherapy combinations, and translational molecular characterization of GEJ tumors. Shah was an investigator in the ToGA trial (Bang et al., Lancet 2010), the landmark phase III study establishing trastuzumab plus chemotherapy as the first HER2-targeted therapy to improve overall survival in HER2-positive advanced gastric/GEJ adenocarcinoma—a watershed moment that introduced molecular subtyping into this disease. He subsequently contributed to second-generation HER2 trials including GATSBY (TDM-1) and INNOVATE (pertuzumab), and has been involved in DESTINY-Gastric series evaluating trastuzumab deruxtecan (T-DXd) in HER2-positive gastric and GEJ cancer after progression on trastuzumab. Beyond HER2, Shah has led and participated in pivotal trials evaluating pembrolizumab (KEYNOTE-590 and KEYNOTE-811), ramucirumab (REGARD, RAINBOW), and zolbetuximab in GEJ/gastric cancer. His translational research program focuses on TCGA-based molecular subtypes of gastric cancer and their predictive relevance to therapy selection. He is co-chair of the ASCO upper GI cancers disease site working group and regularly contributes to NCCN and ASCO clinical practice guidelines.